---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-014231"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:08:16.508049+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

## Summary
- Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
- Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.
- Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).
- Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications.

## SEC filing metadata
- accession: 0001193125-26-014231
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/jagx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-014231
- JSON: https://secwatch.observer/filing/0001193125-26-014231.json
- Plain text: https://secwatch.observer/filing/0001193125-26-014231.txt

## Key facts
- Material Agreements
  Jaguar Health, Inc. entered into License Agreement with Woodward Specialty LLC and Future Pak, LLC valued at $18 million (effective 2026-01-12).
  - Action: entry
  - Agreement: license
  - Counterparty: Woodward Specialty LLC and Future Pak, LLC
  - Value: $18 million
  - Effective: 2026-01-12
  source text: On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation (the “Company”), and the Company, entered into a license agreement (the “License Agreement”) with Woodward Specialty LLC (the “Licensee”), an affiliate of Future Pak, LLC (“Future Pak”), and Future Pak
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm
- Material Agreements
  Jaguar Health, Inc. entered into Supply Agreement with Woodward Specialty LLC and Future Pak, LLC (effective 2026-01-12).
  - Action: entry
  - Agreement: supply
  - Counterparty: Woodward Specialty LLC and Future Pak, LLC
  - Effective: 2026-01-12
  source text: Also on the Effective Date, Napo, Licensee and Future Pak entered into a manufacturing and supply agreement (the “Supply Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.